Key Trial Data Explained at SCAI's Annual Meeting
The Society for Cardiovascular Angiography and Interventions’ (SCAI) upcoming 33rd Annual Scientific Sessions promises the latest news in interventional cardiology from leading experts in the field. The event will take place May 5-8 in San Diego.
This year’s meeting will feature a late-breaking clinical trial surrounding two-year interim results from the single-arm study of the Zilver PTX drug-eluting peripheral stent. William Gray, M.D., will present the data at 11:30 a.m. Pacific time on Friday, May 7.
Additionally, the following notable abstracts will be presented at the meeting:
• One-year results from the EVEREST II High Risk Registry, which examines the safety and efficacy of the transcatheter MitraClip Therapy in relieving symptoms for patients with mitral regurgitation.
• Safety and efficacy data from the ARMOUR trial — a pivotal, prospective, multicenter, nonrandomized trial to evaluate the safety and effectiveness of cerebral protection with the Mo.Ma embolic protection device in high surgical risk subjects undergoing carotid artery stenting (CAS).
• Early findings from the first clinical human study designed to investigate an implantable ST-segment monitoring system that detects and alerts patients to coronary plaque rupture and ischemia.
• Results surrounding the impact of a seven day, 24-hour in-hospital cardiac catheterization lab program on door-to-balloon time in patients presenting with ST-elevated myocardial infarction (STEMI) during off verses regular hours.
• Retrospective review of patients undergoing percutaneous coronary intervention (PCI) and same-day discharge, compared for their appropriateness under the 2009 the American College of Cardiology/American Heart Association/SCAI guidelines on outpatient PCI.
• Hypotheses surrounding the low rate of adoption of transradial access (TRA) for cardiac catheterization in the United States.
Other meeting highlights include a session surrounding practice survival in the era of health care reform, led by Gregory J. Dehmer, M.D., and Edward T. Fry, M.D. Keynote addresses will cover the influence of comparative effectiveness on interventional cardiology; the past, present, and future of stent treatment for congenital heart disease; and a historical perspective of the early days of coronary intervention.
The inauguration of Larry S. Dean, M.D., FSCAI, FACC, FAHA as 33rd president of SCAI will also take place during the annual meeting. Dean recently played an integral role in communicating concerns to the Washington State Health Technology Assessment Committee regarding its proposal to restrict coverage of drug-eluting stents for state-insured employees and Medicaid beneficiaries.
For more information: www.scai.org
More like this
- Drug-Eluting Peripheral Stent Shows Positive Two-Year Data
- Web Exclusive: SCAI to Deliver New Valve Therapy Data at SCAI-ACCi2
- New Study Shows Cook Zilver PTX Effectively Treats Blockages in Critical Thigh Artery
- Organization Promotes Quality Care in Cath Labs
- Transcatheter Mitral Repair Relieves Symptoms Without Surgery